Lupin receives USFDA approval to market Rosuvastatin Calcium
DSIJ Intelligence / 03 Aug 2017
On Thursday, Pharma major Lupin announced that the company has received United States Food and Drug Administration (USFDA) final approval to market Rosuvastatin Calcium Tablet 5 mg, 10 mg, 20 mg and 40 mg.
On Thursday, Pharma major Lupin announced that the company has received United States Food and Drug Administration (USFDA) final approval to market Rosuvastatin Calcium Tablet 5 mg, 10 mg, 20 mg and 40 mg.
The drug is the AB-rated generic equivalent of IPR pharmaceuticals, Inc’s Crestor tablets. It is indicated for the treatment of adult patients with primary dysbetalipoproteinemia, hypertriglyceridemia and adult patients with homozygous familial hypercholesterolemia.
Crestor tablets had US sales of USD 3.4 billion.
At Rs 996 per share on BSE, the stock was trading lower by 3.70% at 1512 hours. It opened at Rs 1,034.80 per share. It attracted traded value of Rs 73,483.80 lakh and a traded volume of 71,89,070 shares on NSE at 1516 hours.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.